ACADIA Pharmaceuticals, Inc.

Acadia Pharmaceuticals published interim results from the LOTUS study showing 71-90% of Rett syndrome patients experienced behavioral improvements with DAYBUE treatment over 12 months.

Major pharmaceutical companies including AstraZeneca, Novartis, and Astellas are defending patents for blockbuster drugs like Lynparza, Entresto, and Xtandi against generic manufacturers in early 2025.

Acadia Pharmaceuticals outlined an ambitious multi-year strategy with a pipeline potentially generating up to $12 billion in annual peak sales across eight clinical programs.

Saniona secured SEK 115 million through warrant exercise and maintains SEK 261 million in cash, strengthening its financial runway to advance three internal neurological programs to Phase 2 trials.

Acadia Pharmaceuticals has appointed Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise, bringing over 20 years of pharmaceutical industry experience.

The U.S. District Court for the District of Delaware ruled in favor of Acadia Pharmaceuticals, upholding their '721 formulation patent for Nuplazid against Aurobindo Pharma's generic challenge.

A U.S. District Court ruled that Aurobindo Pharma infringes on two key patent claims held by Acadia Pharmaceuticals for its Parkinson's disease drug Nuplazid.

The FDA has approved trofinetide (developed by ACADIA Pharmaceuticals) as the first-ever treatment for Rett syndrome, a rare genetic disorder primarily affecting females that causes severe developmental delays and neurological symptoms.

Priority Review Vouchers (PRVs) have surged in value to $150-158 million in recent months, up from the typical $100 million, following Congress's failure to reauthorize the rare pediatric disease program.

Acadia Pharmaceuticals and Saniona successfully completed Phase 1 multiple-ascending-dose study of ACP-711 in healthy volunteers, demonstrating favorable safety and tolerability profile.